| 1 |
Development of a Novel Mechanism-Based Therapeutic Targeting Circulating TXNIP for the Treatment of Insulin Resistance |
| rProtein |
T2D |
TXNIP |
Lead |
Frinsulin Biotech. Co., Ltd. |
RS-2026-25503912 |
|
| 2 |
Development of MASH therapeutics based on AI-guided peptides targeting mitochondrial inner membrane stability |
| rProtein |
MASH |
Cardiolipin |
Lead |
Sungkyunkwan University |
RS-2026-25503089 |
|
| 3 |
Development of Long-Acting FGF21M5-Based Fusion Proteins as Therapeutic Lead for MASH Treatment |
| rProtein |
MASH |
FGFR/KLB |
Lead |
Ewha University-Industry Collaboration Foundation |
RS-2026-25502483 |
|
| 4 |
Development of a Novel Triple Agonist(HM15272)-Based Transdermal Drug Delivery System for Obesity Treatment |
| rProtein |
Obesity |
GLP-1, GIP and Glucagon receptor |
Preclinical |
Hanmi Pharm. Co., Ltd. |
RS-2026-25502086 |
|
| 5 |
Clinical Phase 2 trial of DD01, a Novel Long-acting GLP-1/GCG dual agonist in patients with MASH |
| rProtein |
MASH (Metabolic Associated Steatohepatitis) |
GLP-1/Glucagon receptor |
Phase 2 |
D&D Pharmatech Inc. |
RS-2025-02073063 |
|
| 6 |
Phase 1 clinical development of PG-102, a next-generation GLP-1/GLP-2 dual agonist for treating obesity and diabetes |
| rProtein |
Obesity, Type 2 Diabetes |
GLP-1, GLP-2 수용체 |
Phase 1 |
ProGen Co., Ltd. |
RS-2024-00335179 |
|
| 7 |
Preclinical Development of a UniStac®.based Long.acting Tetraspecific Drug for NASH |
| rProtein |
NASH |
FGF21,GLP.1,GCG,a.cytokine |
Preclinical |
Onegene Biotechnology Inc. |
RS-2023-00282937 |
|
| 8 |
Drug Development for NASH and obesity |
| rProtein |
NASH |
CXCR7 |
Hit |
Yonsei University |
HN22C0645 |
|
| 9 |
Establishing of Fc-flagellin-based candidate drug (MSP-306) for NASH treatment and entering non-clinical trials |
| rProtein |
NASH |
TLR5 |
Candidate |
MediSpan |
HN22C0599 |
|
| 10 |
Pre-clinical study of YH34160 for obesity treatment |
| rProtein |
Obesity |
GDF15 |
Preclinical |
Yuhan |
HN22C0555 |
|
| 11 |
Global Clinical Trial and Commercialization for Development of Next-generation Long-acting Glucagon (HM15136 ) for Congenital Hyperinsulinism (CHI) |
| rProtein |
Congenital hyperinsulinism |
glucagon |
Phase 2 |
Hanmi Pharm. Co., Ltd. |
HN21C0601 |
|
| 12 |
Development of a preclinical candidate of a UniStac-based long-acting tetra-specific drug for NASH |
| rProtein |
NASH |
FGF21, GLP-1, GCG, a-cytokine |
Candidate |
Onegene Biotechnology Inc. |
HN21C0561 |
|
| 13 |
Development of long-acting human growth hormone receptor antagonist by next generation technology |
| rProtein |
Acromegaly |
hGH receptor |
Candidate |
Alteogen Inc. |
HN21C0535 |
|